Biotechnology Financing, Deal-Making and State of the Industry: Findings from EY Industry Analysis, June 5, 1:45-2:45PM, BIO 2018!, Boston, BCEC
Reporter: Aviva Lev-Ari, PhD, RN
1:45 PM–2:45 PMJun 5, 2018
Business Development & Finance
Biotechnology Financing, Deal-Making and State of the Industry: Findings from EY Industry Analysis
Speakers
- Valuation for 23andme?
- Each pool of capital has different investors been attracted
- Science is extraordinary
- A lot of capital and very many tech ventures
- over supply of capital accelerates the business
- More capital is better, understanding in what to invest is critical
- 2015 greatest year of capital availability
- Venture (private) capital (US and Europe)
- Life Sciences M&A – New players and abundant Capital
- Partnering with investors is critical rounds be bigger and faster
- In 16 years rained $4Billion and expenses $2.5Billion
- Orphan Drug for rare disease: Genzyme sold for $18Billion – MS drug
- Immuno-Oncology: Juno and Kite ~$13Billion
- New Theory – came at late stage private company, invest again after iPO then gone
- Investor’s decision if to invest in early stage or come late??
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply